Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Cash | 48.92 | 51.61 | 48.34 | 19.58 |
Cash Equivalents | 62.14 | 0.00 | 6.80 | 2.49 |
Short Term Investments | 176.77 | 98.89 | 48.16 | 65.32 |
Cashand Short Term Investments | 287.82 | 150.50 | 103.30 | 87.39 |
Accounts Receivable- Trade Net | 833.81 | 845.09 | 884.31 | 531.40 |
Total Receivables Net | 1,003.22 | 984.38 | 1,029.27 | 630.38 |
Total Inventory | 630.43 | 729.80 | 722.45 | 429.86 |
Prepaid Expenses | 12.71 | 9.10 | 7.94 | 6.47 |
Other Current Assets Total | 6.71 | 50.39 | 28.66 | 3.31 |
Total Current Assets | 1,940.88 | 1,924.16 | 1,891.62 | 1,157.41 |
Property/ Plant/ Equipment Total- Gross | 2,024.20 | 1,731.88 | 1,504.21 | 1,283.85 |
Accumulated Depreciation Total | -646.97 | -539.37 | -460.30 | -383.23 |
Property/ Plant/ Equipment Total- Net | 1,377.23 | 1,192.50 | 1,043.91 | 900.61 |
Goodwill Net | 2.06 | 2.06 | 2.06 | 15.04 |
Intangibles Net | 6.89 | 5.90 | 5.64 | 5.35 |
Long Term Investments | 3.79 | 7.84 | 16.40 | 27.90 |
Note Receivable- Long Term | 29.54 | 70.82 | 63.84 | 26.15 |
Other Long Term Assets Total | 155.98 | 63.24 | 45.59 | 34.42 |
Total Assets | 3,516.37 | 3,266.53 | 3,069.05 | 2,166.87 |
Accounts Payable | 532.13 | 567.14 | 589.67 | 341.41 |
Accrued Expenses | 48.76 | 37.07 | 33.27 | 25.40 |
Notes Payable/ Short Term Debt | 367.70 | 391.33 | 342.75 | 87.71 |
Current Portof LT Debt/ Capital Leases | 51.33 | 41.17 | 13.31 | 14.90 |
Other Currentliabilities Total | 210.64 | 228.87 | 293.43 | 110.53 |
Total Current Liabilities | 1,210.55 | 1,265.57 | 1,272.42 | 579.95 |
Long Term Debt | 78.30 | 115.50 | 13.33 | 1.16 |
Capital Lease Obligations | 67.91 | 74.88 | 30.41 | 27.87 |
Total Long Term Debt | 146.20 | 190.38 | 43.74 | 29.03 |
Total Debt | 565.23 | 622.87 | 399.80 | 131.64 |
Deferred Income Tax | 12.15 | 25.30 | 39.30 | 41.27 |
Minority Interest | 10.99 | 6.19 | 3.20 | 2.29 |
Other Liabilities Total | 1,426.97 | 1,061.91 | 1,088.42 | 629.49 |
Total Liabilities | 2,806.87 | 2,549.34 | 2,447.07 | 1,282.02 |
Common Stock Total | 28.61 | 28.61 | 14.31 | 1.30 |
Additional Paid- In Capital | 127.17 | 127.17 | 127.17 | 128.29 |
Retained Earnings( Accumulated Deficit) | 553.72 | 561.41 | 480.50 | 755.26 |
Total Equity | 709.50 | 717.19 | 621.98 | 884.85 |
Total Liabilities Shareholders' Equity | 3,516.37 | 3,266.53 | 3,069.05 | 2,166.87 |
Total Common Shares Outstanding | 15.74 | 15.74 | 15.74 | 15.74 |
Tangible Book Valueper Share Common Eq | 44.51 | 45.06 | 39.03 | 54.92 |
Akums Drugs And Pharmaceuticals Dividend Akums Drugs And Pharmaceuticals Bonus Akums Drugs And Pharmaceuticals News Akums Drugs And Pharmaceuticals AGM Akums Drugs And Pharmaceuticals Rights Akums Drugs And Pharmaceuticals Splits Akums Drugs And Pharmaceuticals Board Meetings Akums Drugs And Pharmaceuticals Key Metrics Akums Drugs And Pharmaceuticals Shareholdings Akums Drugs And Pharmaceuticals Profit Loss Akums Drugs And Pharmaceuticals Cashflow Akums Drugs And Pharmaceuticals Q1 Results Akums Drugs And Pharmaceuticals Q2 Results Akums Drugs And Pharmaceuticals Q3 Results Akums Drugs And Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks